Go Pro

TG Therapeutics (TGTX) Earnings Date, Estimates & Call Transcripts

TG Therapeutics logo
$49.76 +0.21 (+0.42%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$49.62 -0.14 (-0.27%)
As of 08/7/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TG Therapeutics Earnings Summary

TG Therapeutics announced Q2 2026 earnings on August 3, 2026, reporting an EPS of $0.05, which missed analysts' consensus estimates of $0.31 by $0.26. Quarterly revenue rose 70.2% year-over-year to $240.34 million, above analyst estimates of $229.77 million. With a trailing EPS of $2.74 and a P/E Ratio of 18.16, TG Therapeutics' earnings are expected to grow 135.59% next year, from $1.18 to $2.78 per share.

Latest Q2
Earnings Date
Aug. 3Estimated
Consensus EPS
(Aug. 3)
$0.31
Actual EPS
(Aug. 3)
$0.05 Missed By -$0.26
Actual Revenue
(Aug. 3)
$240.34M

Q2 2026 Earnings Resources

Get TG Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TG Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

TGTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

TGTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

TG Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue Guidance
Q1 20262$0.17$0.45$0.31
Q2 20262$0.22$0.49$0.36
Q3 20262$0.27$0.46$0.37
Q4 20262$0.37$0.52$0.45

TG Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/3/2026Q2 2026$0.3057$0.05 -$0.2557$0.05$229.77M$240.34M
5/6/2026Q1 2026$0.23$0.12 -$0.11$0.12$200.33M$204.92M
2/26/2026Q4 2025$0.35$0.14 -$0.21$0.14$192.15M$192.57M
11/3/2025Q3 2025$0.24$2.43+$2.19$2.43$152.12M$161.71M
11/3/2025Q3 2025$0.21$2.43+$2.22---
8/4/2025Q2 2025$0.32$0.17 -$0.15$0.17$147.76M$141.15M
5/7/2025Q1 2025$0.19$0.03 -$0.16$0.03$117.07M$120.86M
3/3/2025Q4 2024$0.08$0.15+$0.07$0.15$100.67M$108.19M
11/4/2024Q3 2024$0.03$0.02 -$0.01$0.02$81.68M$83.90M

TG Therapeutics Earnings - Frequently Asked Questions

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earning data on Monday, August 3, 2026. Learn more on TGTX's earnings history.

TG Therapeutics issued an update on its FY 2026 earnings guidance on Monday, August, 3rd. The company issued revenue guidance of $950.0 million-$950.0 million, compared to the consensus revenue estimate of $941.7 million.

In the previous quarter, TG Therapeutics (NASDAQ:TGTX) missed the analysts' consensus estimate of $0.31 by $0.26 with a reported earnings per share (EPS) of $0.05. Learn more on analysts' earnings estimate vs. TGTX's actual earnings.

The conference call for TG Therapeutics' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for TG Therapeutics' latest earnings report can be read online.
Read Transcript

TG Therapeutics (NASDAQ:TGTX) has a recorded annual revenue of $616.29 million.

TG Therapeutics (NASDAQ:TGTX) has a recorded net income of $447.18 million. TGTX has generated $2.74 earnings per share over the last four quarters.

TG Therapeutics (NASDAQ:TGTX) has a trailing price-to-earnings ratio of 18.16 and a forward price-to-earnings ratio of 42.17. The price/earnings-to-growth ratio is 1.65.

TG Therapeutics' earnings are expected to grow from $1.18 per share to $2.78 per share in the next year, which is a 135.59% increase.


Earnings data for NASDAQ:TGTX is sourced from Fiscal.ai, with the most recent quarter reported on 8/3/2026. New results are added as companies report their earnings.
From Our Partners